Consumers Vote RE/MAX the #1 Most Trusted Real Estate Agents in U.S., Canada Once Again
Homebuyers and sellers trust RE/MAX professionals most, according to a leading independent consumer survey.
DENVER, March 25, 2025 /PRNewswire/ -- RE/MAX the #1 name in real estate1, is honored to announce consumers have once again voted RE/MAX® as the brand with the #1 Most Trusted Real Estate Agents in the U.S.2 and Canada3. This esteemed recognition comes from an independent annual survey conducted by the BrandSpark Most Trusted Awards in conjunction with Newsweek magazine. The achievement highlights what truly sets RE/MAX affiliates apart – a steadfast commitment to trust and excellence.
The survey, one of the most comprehensive of its kind, tracks public trust across nearly 300 product and service categories with responses from more than 29,000 shoppers in the U.S. and 35,200 from Canada who shared their unaided, top-of-mind responses on providers they trust and use the most.
This is the fifth time U.S. RE/MAX agents have been recognized for their trustworthiness – and the seventh time in Canada. The survey results speak volumes about the caliber of RE/MAX affiliates, who go above and beyond to prioritize the needs of their clients and have more real estate sales experience than other real estate agents.
"Trust is the foundation of real estate, and we are proud that consumers continue to recognize RE/MAX agents as the most trusted in the business," said RE/MAX Holdings CEO Erik Carlson. "Buying or selling a home is one of the biggest and most important transactions a person will make in their lifetime, so it's critical they work with a trusted professional to guide them through the life-changing transaction."
RE/MAX has long been a trailblazer in the industry, evolving to meet the needs of today's consumers and agents. In 2025, the brand's modern approach includes a bold new advertising campaign that emphasizes the importance of trust in real estate. At the R4® annual event, RE/MAX unveiled a transformative vision, celebrating its trusted agents while announcing initiatives designed to modernize the brand and deliver more value to agents and consumers. From a dynamic influencer program to the introduction of a refreshed balloon logo and RE/MAX logotype and the upcoming launch of a full-service global referral platform, RE/MAX is charting an exciting new chapter to ensure its legacy as a trusted leader.
"Trust is something RE/MAX affiliates are getting even louder about in 2025," said Abby Lee, Executive Vice President of Marketing, Communications and Events at RE/MAX Holdings. "The brand's 2025 ad campaign highlights how aligning with a professional who delivers on trust makes all the difference, and it truly does – it's the number one thing consumers are looking for in an agent."
Carlson added, "As RE/MAX continues to support our incredible community of Broker/Owners, agents and teams, we remain dedicated to providing top-tier service and expertise that build lasting trust with consumers, ensuring the brand's leadership in the industry and positive experiences for homebuyers and sellers."
To view the full BrandSpark Most Trusted Awards and each of its categories, visit https://www.brandsparkmosttrusted.com/usa.
1Source: MMR Strategy Group study of unaided awareness.2Voted most trusted Real Estate Agency brand by American shoppers based on the BrandSpark® American Trust Study, years 2022 – 2025 and 2019.3Voted most trusted Real Estate Agency brand by Canadian shoppers based on the BrandSpark® Canadian Trust Study, years 2021-2025, 2019 and 2017.
About the RE/MAX Network
As one of the leading global real estate franchisors, RE/MAX, LLC is a subsidiary of RE/MAX Holdings (NYSE: RMAX) with more than 145,000 agents in nearly 9,000 offices and a presence in more than 110 countries and territories. Nobody in the world sells more real estate than RE/MAX, as measured by residential transaction sides. RE/MAX was founded in 1973 by Dave and Gail Liniger, with an innovative, entrepreneurial culture affording its agents and franchisees the flexibility to operate their businesses with great independence. RE/MAX agents have lived, worked and served in their local communities for decades, raising millions of dollars every year for Children's Miracle Network Hospitals® and other charities. To learn more about RE/MAX, to search home listings or find an agent in your community, please visit www.remax.com. For the latest news about RE/MAX, please visit news.remax.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/consumers-vote-remax-the-1-most-trusted-real-estate-agents-in-us-canada-once-again-302411236.html
SOURCE RE/MAX, LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
Yahoo
an hour ago
- Yahoo
Vantage Debuts at Wealth Expo Perú 2025 Showcasing Industry Expertise
PORT VILA, Vanuatu, June 12, 2025 /PRNewswire/ -- Vantage Markets is pleased to announce its inaugural participation in Wealth Expo Perú 2025, a notable financial industry events in the region. The event will take place at the prestigious Westin Hotel in San Isidro, the heart of Lima's financial district, bringing together traders, investors, fintech experts, and financial service providers for a full day of knowledge-sharing, networking, and industry discussion. Marking its first-ever appearance at the Peruvian edition of Wealth Expo, Vantage will present its innovative solutions and engage with attendees from the trading and affiliate community. The company's participation will include three speaking sessions led by members of its expert team: Rodrigo Martínez, Team Lead of Business Development, will deliver a keynote on "Vantage: Smart Copy Trading Within Everyone's Reach" – a deep dive into Vantage's intuitive and accessible copy trading platform. He will also join other industry experts on a panel discussing key trends, challenges, and developments within the evolving financial ecosystem in Peru and the wider region. In the workshop track, Julio Vásquez, Business Development Manager, will share insights during his talk: "How to Turn Your Trading and Community into a Passive Income Machine". To kick off the summit in style, Vantage will sponsor an exclusive cocktail reception the evening before the main event. This private gathering will welcome attendees with warm hospitality and an opportunity to connect with the Vantage team in a relaxed setting. Marc Despallieres, CEO of Vantage Markets, shared: "We are pleased to participate in Wealth Expo Perú, an important event within Latin American's growing financial landscape. The region continues to show significant interest in trading and innovation, and we look forward to engaging with industry partners and stakeholders. Through education, technology, and trust, Vantage remains committed to supporting the evolving financial ecosystem." Vantage's growing presence reflects its ongoing commitment to making financial markets more accessible, transparent, and rewarding for traders of all experience levels. For more details on Vantage's initiatives and events, visit Vantage Markets. About Vantage Vantage Markets (or Vantage) is a multi-asset CFD broker offering clients access to a nimble and powerful service for trading Contracts for Difference (CFDs) products, including Forex, Commodities, Indices, Shares, ETFs, and Bonds. With over 15 years of market experience, Vantage transcends the role of broker, providing a reliable trading platform, an award-winning mobile trading app, and a user-friendly trading platform that provide clients access to trading opportunities. trade smarter @vantage RISK WARNING: CFDs are complex instruments and carry a high risk of losing money rapidly due to leverage. Ensure you understand the risks before trading. Disclaimer: This article is provided for informational purposes only and does not constitute financial advice, an offer, or solicitation of any financial products or services. The content is not intended for residents of any jurisdiction where such distribution or use would be contrary to local law or regulation. Readers are advised to seek independent professional advice before making any investment or financial decisions. Any reliance you place on the information presented is strictly at your own risk. View original content to download multimedia: SOURCE Vantage Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
APsystems Unveils Full-Scope AI-Driven Solar & Storage Solutions at SNEC 2025
SHANGHAI, June 12, 2025 /PRNewswire/ -- APsystems made a strong impression at the 18th SNEC PV Power & Energy Storage Expo, held at the National Exhibition and Convention Center in Shanghai. With more than 15 years of disruptive technological innovation, the company introduced its latest advancements in solar and storage technologies, highlighting new products and showcasing the impact of AI integration on energy management. Leading with Innovation: New Product LaunchesAPsystems is introducing the QS2, a brand new single-phase quad microinverter with an impressive 2200W output and support for four high-power PV modules via independent MPPT channels. Designed for safety and efficiency, its module-level architecture keeps DC voltage below 60V during operation, effectively minimizing high-voltage risks. The upgraded Zigbee module enhances communication speed and stability, while the QS2's compatibility with other APsystems single-phase models like the DS3 and QS1 makes system design more flexible. Also introduced was the AHS series Solar Battery Hybrid Controller, designed for off-grid and backup power scenarios. Supporting 12V/24V/48V lead-acid and lithium batteries, the flagship AHS-6.3 delivers a 6300VA pure sine wave output with 99.9% MPPT efficiency and seamless 5ms UPS switching. With IP43 cooling and real-time app monitoring, it's built for reliability in both home and telecom applications. Versatile Solar + Storage Solutions for Every NeedAPsystems highlighted its complete lineup of distributed energy solutions across micro, residential, and commercial applications. The EZ1/EZHI series empower DIY users with microgrid capabilities and energy independence. For residential settings, 20A microinverters and ELS/ELT storage options provide flexible options. In the C&I space, the QT2 three-phase microinverters and Ocean series storage systems are designed for cost efficiency and scalable performance. Smarter Energy with AI IntegrationA major focus this year was APsystems' AI-driven enhancements. The new BESS AI model uses deep learning to forecast energy generation and consumption based on historical data and local energy prices. This enables automatic, personalized charge/discharge schedules for balcony and residential storage systems—delivering smarter, more efficient energy use. APsystems also unveiled APbot, a smart support assistant built on advanced AI architecture using private LLM deployment and RAG technology. Designed to improve customer interaction, APbot delivers fast, accurate responses using semantic search and knowledge-based reasoning, all while being easily adaptable for global compliance needs. The AP Designer tool also received an AI boost. Now featuring image recognition, real-time simulation, and 3D modeling, it streamlines PV design by analyzing rooftops, trees, and shading. With online design capabilities and automatic report generation, it simplifies everything from planning to budget forecasting. Thank you to everyone who visited our booth at SNEC 2025. We appreciate your interest and look forward to connecting again next time! View original content to download multimedia: SOURCE Altenergy Power System Inc.
